In recent years, immunotherapy has significantly changed the treatment of locally
advanced/metastatic non-small-cell lung cancer (NSCLC). Conversely, the role of …

Recent developments in immunotherapy have significantly improved the survival outcomes
of patients with various types of cancers including thoracic malignancies. In this chapter, we …

Lung cancer is one of the most commonly diagnosed cancers and the leading cause of
cancer-related deaths worldwide. Although progress in the treatment of advanced non-small …

Lung cancer is a malignant tumor with the highest morbidity and mortality in the world. Non-
small cell lung cancer (NSCLC) is the most common pathological type; however, the effects …

Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune
checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed …

From radiation therapy and surgery to chemotherapy and targeted therapy, the treatment of
non-small cell lung cancer (NSCLC) has remarkably evolved over the past few decades. In …

The treatment paradigm for lung cancer has been transformed in recent years by the use of
immunotherapy, specifically, immune checkpoint antibodies (mAb), which are agents …

For decades, immunotherapy strategies have failed to succeed in lung cancer. However, the
recent success of immune checkpoint inhibitors and the progress in the understanding of the …

The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment
paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small …

Lung cancer remains the most common cause of cancer-related deaths worldwide. Although
there are many possible treatments, including targeted therapies such as epidermal growth …